Log in | Register

Bleeding and risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial

Nicolai Haase| Jørn Wetterslev| Per Winkel| Anders Perner
Original Article
Volume 39, Issue 12 / December , 2013

Pages 2126 - 2134

Abstract

Purpose

We aimed to characterize the degree and clinical importance of bleeding in patients treated with hydroxyethyl starch (HES).

Methods

In post hoc analyses, we examined the associations between fluid assignment, hemostatic variables, bleeding events, transfusions, and death among 798 patients with severe sepsis randomized to fluid resuscitation with HES 130/0.42 versus Ringer’s acetate. We used Cox regression analysis adjusted for fluid assignment and baseline characteristics.

Results

Overall, 93 (23 %) patients assigned to HES versus 60 (15 %) patients assigned to Ringer’s acetate bled in the ICU (relative risk (RR) 1.55; 95 % CI 1.16–2.08; P = 0.003). Of these, 38 and 25 (RR 1.52; 95 % CI 0.94–2.48; P = 0.09), respectively, had severe bleeding (intracranial or concomitant transfusion with three units of red blood cells). Most patients bled in the first days after randomization when most trial fluid was given. The hazards ratios for occurrence of any bleeding and severe bleeding in patients treated with HES versus Ringer’s acetate were 1.70 (95 % CI 1.23–2.36; P = 0.001) and 1.55 (95 % CI 0.93–2.56; P = 0.09), respectively. The adjusted hazard ratios for death among patients with any bleeding and severe bleeding compared to those without bleeding were 1.36 (95 % CI 1.04–1.79; P = 0.03) and 1.74 (95 % CI 1.20–2.53; P = 0.004), respectively.

Conclusions

In post hoc analyses of patient with severe sepsis, treatment with HES increased the risk of bleeding which was associated with increased risk of death. HES-induced bleeding complications may negatively affect outcome in patients with severe sepsis.

Keywords

References

  1. Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D, Du B, McArthur C, Myburgh J (2010) Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units. Crit Care 14:R185. doi:10.1186/cc9293
    • View reference on PubMed
    • View reference on publisher's website
  2. Groeneveld A, Navickis R, Wilkes M (2011) Update on the comparative safety of colloids: a systematic review of clinical studies. Ann Surg 253:470–483. doi:10.1097/SLA.0b013e318202ff00
    • View reference on PubMed
    • View reference on publisher's website
  3. Navickis RJ, Haynes GR, Wilkes MM (2012) Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass: a meta-analysis of randomized trials. J Thorac Cardiovasc Surg 144:223–230. doi:10.1016/j.jtcvs.2012.04.009
    • View reference on PubMed
    • View reference on publisher's website
  4. Hartog CS, Reuter D, Loesche W, Hofmann M, Reinhart K (2011) Influence of hydroxyethyl starch (HES) 130/0.4 on hemostasis as measured by viscoelastic device analysis: a systematic review. Intensive Care Med 37:1725–1737. doi:10.1007/s00134-011-2385-z
  5. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, Madsen KR, Møller MH, Elkjær JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Søe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjældgaard A-L, Fabritius ML, Mondrup F, Pott FC, Møller TP, Winkel P, Wetterslev J (2012) Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 367:124–134. doi:10.1056/NEJMoa1204242
    • View reference on PubMed
    • View reference on publisher's website
  6. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125–139. doi:10.1056/NEJMoa070716
    • View reference on PubMed
    • View reference on publisher's website
  7. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SAR (2012) Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367:1901–1911. doi:10.1056/NEJMoa1209759
    • View reference on PubMed
    • View reference on publisher's website
  8. Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S (2013) Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 39:558–568. doi:10.1007/s00134-013-2840-0
  9. Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, Fergusson DA (2013) Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 309:678–688. doi:10.1001/jama.2013.430
    • View reference on PubMed
    • View reference on publisher's website
  10. Perel P, Roberts I, Ker K (2013) Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2: CD000567. doi:10.1002/14651858.CD000567.pub6
  11. The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee. PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl-starch (2013). http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Solutions_for_infusion_containing_hydroxyethyl_starch/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500144448.pdf. Accessed 14 Jun 2013
  12. US Food and Drug Administration (2013) FDA safety communication: Boxed warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm358271.htm. Accessed 24 Jun 2013
  13. Perner A, Haase N, Wetterslev J, Aneman A, Tenhunen J, Guttormsen AB, Klemenzson G, Pott F, Bødker KD, Bådstøløkken PM, Bendtsen A, Søe-Jensen P, Tousi H, Bestle M, Pawlowicz M, Winding R, Bülow H–H, Kancir C, Steensen M, Nielsen J, Fogh B, Madsen KR, Larsen NH, Carlsson M, Wiis J, Petersen JA, Iversen S, Schøidt O, Leivdal S, Berezowicz P, Pettilä V, Ruokonen E, Klepstad P, Karlsson S, Kaukonen M, Rutanen J, Karason S, Kjældgaard AL, Holst LB, Wernerman J (2011) Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S–Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationale for a double-blinded, randomised clinical trial. Trials 12:24. doi:10.1186/1745-6215-12-24
    • View reference on PubMed
    • View reference on publisher's website
  14. Kahan BC, Morris TP (2012) Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis. BMJ 345:e5840
    • View reference on PubMed
    • View reference on publisher's website
  15. Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–63
  16. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710
  17. Gabriel SE, Normand S-LT (2012) Getting the methods right–the foundation of patient-centered outcomes research. N Engl J Med 367:787–790. doi:10.1056/NEJMp1207437
    • View reference on PubMed
    • View reference on publisher's website
  18. Schafer JL (1999) Multiple imputation: a primer. Stat Methods Med Res 8:3–15
    • View reference on PubMed
    • View reference on publisher's website
  19. Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P (2008) The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesth Analg 107:382–390. doi:10.1213/ane.0b013e31817e6eac
    • View reference on PubMed
    • View reference on publisher's website
  20. Westphal M, James MFM, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H (2009) Hydroxyethyl starches: different products–different effects. Anesthesiology 111:187–202. doi:10.1097/ALN.0b013e3181a7ec82
    • View reference on PubMed
    • View reference on publisher's website
  21. Godier A, Durand M, Smadja D, Jeandel T, Emmerich J, Samama CM (2010) Maize- or potato-derived hydroxyethyl starches: is there any thromboelastometric difference? Acta Anaesthesiol Scand 54:1241–1247. doi:10.1111/j.1399-6576.2010.02306.x
    • View reference on PubMed
    • View reference on publisher's website
  22. Matsota P, Politou M, Kalimeris K, Apostolaki S, Merkouri E, Gialeraki A, Travlou A, Kostopanagiotou G (2010) Do different substitution patterns or plant origin in hydroxyethyl starches affect blood coagulation in vitro? Blood Coagul Fibrinolysis 21:448–451. doi:10.1097/MBC.0b013e328338db67
    • View reference on PubMed
    • View reference on publisher's website
  23. Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, Forceville X, Feissel M, Hasselmann M, Heininger A, Van Aken H (2012) Assessment of hemodynamic efficacy and safety fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care 16:R94. doi:10.1186/11358
    • View reference on PubMed
    • View reference on publisher's website
  24. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J (2013) Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 346:f839
    • View reference on PubMed
    • View reference on publisher's website
  25. Stanworth SJ, Morris TP, Gaarder C, Goslings JC, Maegele M, Cohen MJ, König TC, Davenport RA, Pittet J-F, Johansson PI, Allard S, Johnson T, Brohi K (2010) Reappraising the concept of massive transfusion in trauma. Crit Care 14:R239. doi:10.1186/cc9394
    • View reference on PubMed
    • View reference on publisher's website
  26. Shaw AD, Kellum JA (2013) The risk of AKI in patients treated with intravenous solutions containing hydroxyethyl starch. Clin J Am Soc Nephrol 8:497–503. doi:10.2215/CJN.10921012
    • View reference on PubMed
    • View reference on publisher's website
  27. Finfer S, Liu B, Chittock DR, Norton R, Myburgh JA, McArthur C, Mitchell I, Foster D, Dhingra V, Henderson WR, Ronco JJ, Bellomo R, Cook D, McDonald E, Dodek P, Hébert PC, Heyland DK, Robinson BG (2012) Hypoglycemia and risk of death in critically ill patients. N Engl J Med 367:1108–1118. doi:10.1056/NEJMoa1204942
    • View reference on PubMed
    • View reference on publisher's website
  28. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E, Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 340:409–417. doi:10.1056/NEJM199902113400601
    • View reference on PubMed
    • View reference on publisher's website
  29. Lieberthal W, Fuhro R, Alam H, Rhee P, Szebeni J, Hechtman HB, Favuzza J, Veech RL, Valeri CR (2002) Comparison of the effects of a 50% exchange-transfusion with albumin, hetastarch, and modified hemoglobin solutions. Shock 17:61–69
    • View reference on PubMed
    • View reference on publisher's website
  30. Schick MA, Isbary JT, Stueber T, Brugger J, Stumpner J, Schlegel N, Roewer N, Eichelbroenner O, Wunder C (2012) Effects of crystalloids and colloids on liver and intestine microcirculation and function in cecal ligation and puncture induced septic rodents. BMC Gastroenterol 12:179. doi:10.1186/1471-230X-12-179
    • View reference on PubMed
    • View reference on publisher's website
  31. Abraham E, Singer M (2007) Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 35:2408–2416
    • View reference on PubMed
    • View reference on publisher's website
  32. Von Heymann C, Sander M, Spies CD (2012) Protocols, physiology, and trials of hydroxyethyl starch. N Engl J Med 367:1265–1266. doi:10.1056/NEJMc1209905#SA2 author reply 1267
    • View reference on publisher's website
  33. Wise R, Fourie C, Richards GA (2012) Protocols, physiology, and trials of hydroxyethyl starch. N Engl J Med 367:1266–1267. doi:10.1056/NEJMc1209905#SA4 author reply 1267
    • View reference on PubMed
  34. Magder S (2012) Protocols, physiology, and trials of hydroxyethyl starch. N Engl J Med 367:1265. doi:10.1056/NEJMc1209905#SA1 author reply 1267
    • View reference on PubMed
    • View reference on publisher's website
  35. Chappell D, Jacob M (2012) Protocols, physiology, and trials of hydroxyethyl starch. N Engl J Med 367:1266. doi:10.1056/NEJMc1209905#SA3 author reply 1267
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement